Enliven
ELVNEnliven Therapeutics, Inc. Price (ELVN)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
47,072,532
(32.4263)%
Community Sentiment
0 votes
↑ 0%
↓ 0%
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado. Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $14.5-30.03
- Market Cap 990.86M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Mr. Samuel S. Kintz M.B.A.
- IPO Date: March, 12, 2020
- Country: US
- Currency: USD
- Headquaters: Boulder, CO
- Employees: 62
- Revenue from each product or segment:
| Product or Segment | Value: | % - Total | Last 3Y: |
|---|
- Revenue by Region
| Product or Segment | Value: | % - Total | Last 3Y: |
|---|